YD Bio (YDES) Non-Current Assets (2024 - 2025)
YD Bio's (YDES) quarterly Non-Current Assets came in at -$9670.2 billion in Q4 2025, down 178.85% year-on-year from $12264.0 billion in Q4 2024, and down 217588878.22% on a QoQ basis from $4.4 million in Q2 2025.
YD Bio (YDES) Non-Current Assets (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Non-Current Assets data on file, last reported at -$9670.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | -9,670.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9,670.18 Bn |
| Jun 30, 2025 | 4.44 Mn |
| Dec 31, 2024 | -3,467.88 Bn |